These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 29279690)

  • 1. Immune Checkpoint Inhibitor-Associated Type 1 Diabetes Mellitus: Case Series, Review of the Literature, and Optimal Management.
    Kapke J; Shaheen Z; Kilari D; Knudson P; Wong S
    Case Rep Oncol; 2017; 10(3):897-909. PubMed ID: 29279690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
    Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
    Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors.
    Marchand L; Disse E; Dalle S; Reffet S; Vouillarmet J; Fabien N; Thivolet C; Cugnet-Anceau C
    Acta Diabetol; 2019 Dec; 56(12):1239-1245. PubMed ID: 31423559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.
    Hickmott L; De La Peña H; Turner H; Ahmed F; Protheroe A; Grossman A; Gupta A
    Target Oncol; 2017 Apr; 12(2):235-241. PubMed ID: 28255845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
    Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of checkpoint immunotherapy for the management of non-small cell lung cancer.
    Raju S; Joseph R; Sehgal S
    Immunotargets Ther; 2018; 7():63-75. PubMed ID: 30105218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
    Hoffner B; Leighl NB; Davies M
    Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.
    Bellmunt J; Powles T; Vogelzang NJ
    Cancer Treat Rev; 2017 Mar; 54():58-67. PubMed ID: 28214651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations.
    Wang GX; Guo LQ; Gainor JF; Fintelmann FJ
    AJR Am J Roentgenol; 2017 Sep; 209(3):567-575. PubMed ID: 28657846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
    J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab induced new-onset type 1 diabetes mellitus.
    de Carlos J; Zabalza L; Garcia J; Marti M; Ayarza-Marien X; Yoldi J
    J Oncol Pharm Pract; 2023 Jul; 29(5):1268-1270. PubMed ID: 36635950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 checkpoint inhibition: Toxicities and management.
    Hahn AW; Gill DM; Agarwal N; Maughan BL
    Urol Oncol; 2017 Dec; 35(12):701-707. PubMed ID: 28889921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies.
    Ferrari SM; Fallahi P; Elia G; Ragusa F; Ruffilli I; Patrizio A; Galdiero MR; Baldini E; Ulisse S; Marone G; Antonelli A
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Blockade Anti-PD-L1 as a Trigger for Autoimmune Polyendocrine Syndrome.
    Lanzolla G; Coppelli A; Cosottini M; Del Prato S; Marcocci C; Lupi I
    J Endocr Soc; 2019 Feb; 3(2):496-503. PubMed ID: 30746508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.
    Curry JL; Tetzlaff MT; Nagarajan P; Drucker C; Diab A; Hymes SR; Duvic M; Hwu WJ; Wargo JA; Torres-Cabala CA; Rapini RP; Prieto VG
    J Cutan Pathol; 2017 Feb; 44(2):158-176. PubMed ID: 27859479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune Diabetes and Thyroiditis Complicating Treatment with Nivolumab.
    Li L; Masood A; Bari S; Yavuz S; Grosbach AB
    Case Rep Oncol; 2017; 10(1):230-234. PubMed ID: 28611636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.